HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol?

Abstract

Psoriasis is a chronic inflammatory skin disease characterized by erythematous plaques with scales mainly localized at the elbows, knees, and the trunk, but, which can affect all skin areas including the scalp or genital area. To the date, many drugs are developed to treat this condition, in particular biological treatments are the most important therapy that are used to control the disease. We read with very interesting the paper published on January 16 by Sin et al 1 regarding the role of the Human Leukocyte Antigen C06 (HLA‐C*06) in Chinese patients with active peripheral type psoriatic arthritis. The authors enrolled 60 patients but only 47 patients were genotyping for HLA‐C*06. The result showed HLA‐C*07:02 was the most frequent allele (29.8%), followed by HLA‐C*01 (26.6%). The frequency of HLA‐C*06:02 alleles was similar to Chinese normal population. We present data from our study conducted in patients with psoriatic arthritis (PsA) and chronic plaque psoriasis treated with certolizumab pegol and despite previous methotrexate, cyclosporine, anti‐inflammatory drugs (NSAIDs), and corticosteroids; other authors reported similar data in response to adalimumab and ustekinumab. 2 , 3